Supporters so far
HOOFING IT! 2026 Total so far $10,685
Start Hoofing It! Registration is open join a team or start your own Register Now
2025 Results Together we raised $40,662 — thank you to all 150 donors & 11 teams Donate Today
Why It Matters Every step funds NET research, drug access, & patient support across Canada Learn More
Sponsor a Walker Can’t walk? Sponsor a team member — every dollar counts Sponsor Now
2026 Total So Far $10,685 raised of $60,000 — keep on HOOFING IT! Donate Now
HOOFING IT! 2025:
Raised $40,662!

Somatuline (lanreotide) Access in Manitoba & Alberta

As we advised previously, in July of this year the Manitoba government issued a bulletin http://www.gov.mb.ca/health/mdbif/…/bulletins/bulletin93.pdf that indicated a change in the listing for Somatuline (from 1 to 3 and no access for NET patients in Manitoba). While CNETS Canada did not get a satisfactory response from the Assistant Deputy Minister Provincial Policy and Programs Division on the reason for the change, we have learned recently that a reversal of this decision is forthcoming.   If there are any Manitoba patients facing access issues we would like to hear from you.   Please contact Jackie.herman@cnetscanada.org

Somatuline is currently not covered for NETs in Alberta.  Any Albertan patients who are experiencing issues gaining access to Somatuline please reach out to Jackie.herman@cnetscanada.org

By |2018-05-07T18:28:11-04:00October 2nd, 2017|Treatment News|Comments Off on Somatuline (lanreotide) Access in Manitoba & Alberta

Share This Story, Choose Your Platform!

About the Author:

Go to Top